| Drug Name | ( TYKERB (LAPATINIB |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Comparative data have shown that Lapatinib based regimens are less effective than trastuzumab based regimens in certain settings |
| Dear Healthcare provider letter DHPC |
|